warning_amberWhat You Should Know

Compounded Tirzepatide

Why compounded tirzepatide became widespread during the shortage, what the FDA's resolved status changed, and how the legal and clinical picture looks in 2026.

Tirzepatide is the dual GIP/GLP-1 agonist in Mounjaro and Zepbound. Compounded versions appeared when Eli Lilly's pre-filled pens went on the FDA shortage list in late 2022. For roughly two years, compounding pharmacies — many of them paired with telehealth platforms — sold compounded tirzepatide at a fraction of brand-name pricing.

That ended, at least in its broad form, when the FDA declared the shortage resolved in October 2024. After litigation and a transition window, compounding pharmacies were expected to stop preparing tirzepatide for general use, with the final clarifying guidance issued in December 2024. The regulatory dust is still settling in 2026, but the days of buying compounded tirzepatide on a subscription from a slick telehealth site are largely over.

This guide covers what compounded tirzepatide is, why the FDA pulled back, the specific risks documented in the published safety record, and the practical options if you've been using a compounded version.

What it actually is

A compounded drug is prepared by a pharmacy rather than a manufacturer. It is not FDA-approved as a finished product. During an official FDA-listed shortage of an approved drug, federal law allows compounding pharmacies to prepare versions of that drug to bridge supply. That is the legal basis on which compounded tirzepatide was prepared in 2022–2024.

Two categories of pharmacy did most of the compounding. 503A pharmacies are state-licensed traditional compounding pharmacies that prepare patient-specific prescriptions. 503B outsourcing facilities are federally registered facilities that meet stricter manufacturing standards and can make larger batches without an individual patient prescription. Both categories prepared compounded tirzepatide during the shortage, often as a multi-dose vial with a separate syringe rather than the click-pen format Eli Lilly sells.

Tirzepatide is more complex to synthesize than older peptides. It is a 39-amino-acid chain with a fatty acid side group, and the manufacturing-grade product Eli Lilly makes is the only formulation that has been clinically validated. The active pharmaceutical ingredient (API) in compounded versions came from third-party suppliers, often outside the United States, with varying quality records.

Where things stand in 2026

The FDA added tirzepatide to the drug shortage list in December 2022. As supply caught up through 2024, Eli Lilly publicly stated it had met U.S. demand. The FDA initially declared the shortage resolved in October 2024. Compounding industry groups sued to delay enforcement, and the FDA paused action briefly before issuing a final clarifying determination in December 2024.

Under that final position, 503A pharmacies were given a short transition window to stop compounding tirzepatide, and 503B outsourcing facilities were given a slightly longer one — both windows had closed by mid-2025. As of 2026, broad commercial compounding of tirzepatide for routine weight management is no longer legally protected.

What replaced it for cash-pay patients is LillyDirect, Eli Lilly's direct-to-consumer self-pay program. LillyDirect ships single-dose vials of Zepbound at fixed monthly prices that are meaningfully lower than retail (currently in the $299–$449 range depending on strength). That price is higher than most compounded versions were in 2023, but it is an FDA-approved product with manufacturer quality controls.

Some 503A pharmacies still argue for patient-specific clinical exceptions — for example, a documented intolerance to an inactive ingredient in Zepbound. Whether those exceptions hold up depends on the case, the state, and current FDA enforcement priorities.

The real risks

The FDA's documented harms from compounded tirzepatide mirror what it has reported for compounded semaglutide. Dosing errors top the list. Compounded tirzepatide is typically shipped as a vial that the patient draws into a syringe, often labeled in milligrams. Patients used to insulin syringes labeled in "units" have repeatedly drawn 10 times the intended dose. Severe nausea, vomiting, dehydration, and emergency-room visits have followed.

Identity and potency are the other major cluster. The FDA does not test compounded products for potency or content uniformity. Some compounded tirzepatide products have been tested by third parties and shown variation in actual peptide content from labeled values. Sterility for an injectable, multi-dose vial requires aseptic technique that not every 503A pharmacy is built to maintain consistently.

What to watch for

warning

Dosing errors

Tirzepatide doses (2.5 mg, 5 mg, 7.5 mg) look like very small volumes in a syringe. Mixing up 'mg' with 'units' or misreading the syringe scale has caused 10x overdoses serious enough to land patients in the ER. If you're transitioning a compounded prescription, ask for a written draw chart.

biotech

Identity and potency

Compounded tirzepatide can vary in actual peptide content from what the label says. The FDA does not test compounded products for potency, identity, or sterility. Third-party testing has shown product-to-product variability.

verified_user

Pharmacy verification

Check the pharmacy's license with your state board. For a 503B outsourcing facility, confirm it's on the FDA's published 503B registration list. Ask in writing about API source, salt form, and potency testing — any pharmacy unwilling to answer is a red flag.

Common questions

Common Concerns

Is compounded tirzepatide still available in 2026?expand_more

Not broadly, and not for routine weight management through telehealth subscriptions. The FDA's December 2024 final guidance ended the shortage-driven legal cover. Patient-specific compounding for documented clinical needs may still happen on a case-by-case basis, but the large-scale commercial channels that existed in 2023–2024 have largely closed. Rules continue to evolve.

What replaced compounded tirzepatide for cash-pay patients?expand_more

LillyDirect, Eli Lilly's direct-to-consumer pharmacy, sells single-dose Zepbound vials at fixed monthly self-pay prices ($299 for 2.5 mg, $399 for 5 mg, $449 for 7.5 mg and higher as of early 2026). It is an FDA-approved product with manufacturer quality control. The vial format requires drawing each dose into a syringe — similar workflow to compounded, but with a verified product.

Can I switch from compounded tirzepatide to Zepbound?expand_more

Yes. Most patients transition by getting a prescription for Zepbound (or Mounjaro for diabetes) from their prescriber. Dose conversion is not always one-to-one because compounded doses were often customized. Your provider may resume the standard titration schedule or hold you at a similar weekly milligram dose. Discuss the transition specifically — don't assume the doses are interchangeable.

Why is brand tirzepatide more expensive than compounded was?expand_more

Brand tirzepatide reflects Eli Lilly's research, FDA approval, manufacturing under cGMP standards, and quality testing. Compounded versions skipped all of that, sourced bulk API (often imported) at a fraction of the cost, and prepared multi-dose vials that are cheap to fill. The price gap reflected a regulatory and quality gap, not just margin.

How do I verify a compounding pharmacy if I'm still considering one?expand_more

Look up the pharmacy with your state board of pharmacy. Check whether it's been the subject of FDA warning letters (searchable on FDA's site). For 503B facilities, confirm registration on FDA's 503B list. Ask the pharmacy in writing for the API supplier name, FDA registration of that supplier, the salt form they use, and their potency and sterility testing process. Reputable pharmacies will provide this.

Keep exploring

Browse all dosing guides.